This is a working overview of reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-26 and is reviewed periodically as new material appears.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid in a sealed vial |
| Solubility class | Soluble in water and polar organic solvents | Reconstituted solutions are generally clear |
| Typical storage temperature | -20 degrees Celsius or below, dry | Protect from light; avoid repeated freeze-thaw cycles |
| Common analytical methods | Reversed-phase HPLC-UV, LC-MS | Used for purity estimation and mass confirmation |
| Reported purity range | Area percentage above 95 percent | Reporting practice and acceptance limits differ by laboratory |
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
=== Deregulation in cancer === Cyclin D1 overexpression has been shown to correlate with early cancer onset and tumor progression and it can lead to oncogenesis by increasing anchorage-independent growth and angiogenesis via VEGF production. Cyclin D1 overexpression can also down-regulate Fas expression, leading to increased chemotherapeutic resistance and protection from apoptosis. An abundance of cyclin D1 can be caused by various types of deregulation, including:
Gabapentinoids, also known as α2δ ligands, are a class of drugs that are chemically derivatives of the inhibitory neurotransmitter gamma-Aminobutyric acid (GABA) (i.e., GABA analogues) which bind selectively to the α2δ protein that was first described as an auxiliary subunit of voltage-gated calcium channels (VGCCs). Clinically used gabapentinoids include gabapentin, pregabalin, baclofen and mirogabalin, as well as a gabapentin prodrug, gabapentin enacarbil. Further analogues like imagabalin and atagabalin have been tested in clinical trials but their development has been halted. Other gabapentinoids which are used in scientific research but have not been approved for medical use include 4-methylpregabalin and PD-217,014.
Futurist Ray Kurzweil has shown some concern that, within the century, humans may be required to merge with this technology in order to compete in the marketplace. Enhanced individuals have a better chance of being chosen for better opportunities in careers, entertainment and resources. For example, life-extending technologies can increase the average individual life span, affecting the distribution of pension throughout the society. Increasing lifespan will affect human population, further dividing limited resources such as food, energy, monetary resources and habitat. Other critics of human enhancement fear that such capabilities would change, for the worse, the dynamic relations within a family. Given the choices of superior qualities, parents make their child as opposed to merely birthing it, and the newborn becomes a product of their will rather than a gift of nature to be loved unconditionally.
=== Environment and sustainability === As global populations rise, food demand is becoming an increasingly important issue. Raising conventional livestock requires resources such as land and water, of which availability is concurrently decreasing. As a result, the ability to meet the needs of the growing population may require alternative sources of quality protein. As the global population rises, there is an increasing demand for animal-based proteins that will require the use of alternative and sustainable sources for pet food as well. Pets play an important role in society, providing companionship and support, and owning pets has been linked to reduced incidence of heart disease, stress and depression. The popularity of pet ownership is increasing, and with this is a trend of humanization. People are increasingly demanding pet food ingredients that they believe are healthy. This creates a competition with the human food chain for quality protein sources. Producing insect protein through other agricultural practices requires considerably less resources than traditional livestock. The production of insects also produces lower greenhouse gases and ammonia than traditional livestock species. Insects also have the ability to feed on organic waste products such as vegetable, restaurant and animal waste, therefore reducing the amount of excess food produced by humans. Insects are very efficient at converting feed into protein, as they require less feed than traditional livestock.
Sources: en.wikipedia.org
=== Water vapor capture and dehumidification === Some MOFs can capture water vapor from ambient air. In 2021 under humid conditions, a polymer-MOF lab prototype yielded 17 liters (4.5 gal) of water per kg per day without added energy. MOFs can be used to increase energy efficiency in room temperature space cooling applications.
Degeneracy is the redundancy of the genetic code. This term was given by Bernfield and Nirenberg. The genetic code has redundancy but no ambiguity (see the codon tables below for the full correlation). For example, although codons GAA and GAG both specify glutamic acid (redundancy), neither specifies another amino acid (no ambiguity). The codons encoding one amino acid may differ in any of their three positions. For example, the amino acid leucine is specified by YUR or CUN (UUA, UUG, CUU, CUC, CUA, or CUG) codons (difference in the first or third position indicated using IUPAC notation), while the amino acid serine is specified by UCN or AGY (UCA, UCG, UCC, UCU, AGU, or AGC) codons (difference in the first, second, or third position). A practical consequence of redundancy is that errors in the third position of the triplet codon cause only a silent mutation or an error that would not affect the protein because the hydrophilicity or hydrophobicity is maintained by equivalent substitution of amino acids; for example, a codon of NUN (where N = any nucleotide) tends to code for hydrophobic amino acids. NCN yields amino acid residues that are small in size and moderate in hydropathicity; NAN encodes average size hydrophilic residues. The genetic code is so well-structured for hydropathicity that a mathematical analysis (Singular Value Decomposition) of 12 variables (4 nucleotides x 3 positions) yields a remarkable correlation (C = 0.95) for predicting the hydropathicity of the encoded amino acid directly from the triplet nucleotide sequence, without translation.
So what can it mean when America says it will now protect its friends? It can only mean prejudice against Iraq. This stance plus maneuvers and statements which have been made has encouraged the UAE and Kuwait to disregard Iraqi rights ... If you use pressure, we will deploy pressure and force. We know that you can harm us although we do not threaten you. But we too can harm you. Everyone can cause harm according to their ability and their size. We cannot come all the way to you in the United States, but individual Arabs may reach you ... We do not place America among the enemies. We place it where we want our friends to be and we try to be friends. But repeated American statements last year made it apparent that America did not regard us as friends. Glaspie replied:
Sources: en.wikipedia.org
== History == 3M (then the Minnesota Mining and Manufacturing Company) began producing PFOA by electrochemical fluorination in 1947. Starting in 1951, DuPont purchased PFOA from 3M for use in the manufacturing of specific fluoropolymers—commercially branded as Teflon—but DuPont internally referred to PFOA as C8. In 1968, organofluorine content was detected in the blood serum of consumers, and in 1976 it was suggested to be PFOA or a related compound such as PFOS. In 1999, EPA ordered companies to examine the effects of perfluorinated chemicals after receiving data on the global distribution and toxicity of PFOS. For these reasons, and EPA pressure, in May 2000, 3M announced the phaseout of the production of PFOA, PFOS, and PFOS-related products—the company's best-selling repellent. 3M stated that they would have made the same decision regardless of EPA pressure. Because of the 3M phaseout, in 2002, DuPont built its own plant in Fayetteville, North Carolina, to manufacture the chemical. The chemical has received attention due to litigation from the PFOA-contaminated community around DuPont's Washington Works facility in Washington, West Virginia, along with EPA focus. In 2004, ChemRisk—an "industry risk assessor" that had been contracted by Dupont, reported that over 1.7 million pounds of C8 had been "dumped, poured and released" into the environment from Dupont's Parkersburg, West Virginia-based Washington Works plant between 1951 and 2003.
=== Electric vehicles === In February 2023, Moore introduced the Clean Transportation and Energy Act, which increases incentives for people and businesses looking to purchase electric trucks and charging stations. In March 2023, he said he supported adopting California's Advanced Clean Cars II (ACC II) regulation, which would phase out the sale of gas-powered cars in the state by 2035. In April 2023, he signed the Clean Transportation and Energy Act and several other bills aimed at strengthening the state's offshore wind energy industry into law. In August 2023, Moore said he supported a proposal by then-Governor Hogan to delay emissions testing on new cars from three to six years—despite initially withdrawing the proposal earlier in his term due to equity concerns—after the Maryland Motor Vehicle Administration found that the change would have no severe impacts on equity. In April 2025, as Maryland electric vehicle sales continued to lag behind the state's goals, Moore signed an executive order to delay fines against car companies that fail to comply with the state's electric vehicle mandates.
== Criticism and controversies == UPMC has been criticized for excessive profits, monopolistic practices, excessive advertising budgets, and focusing on overseas operations at the expense of domestic ones. In addition, various controversies have received significant local and national attention in recent years. Over the last decade, it has often found itself the target of pointed criticisms from SEIU Healthcare, which has tried unsuccessfully to organize bargaining units among UPMC's service employees and other front-line workers. In 2008, the administration and reporting of UPMC's living donor liver transplantation program received national attention when internal studies, spearheaded by transplant pioneer Thomas Starzl, questioned the safety of the procedure and ultimately resulted in the forced resignation of liver transplant program head, Amadeo Marcos. Another controversy arose in May 2011 for UPMC's live-donor kidney transplant program when a kidney infected with hepatitis C was transplanted into a non-infected person. The incident led UPMC to voluntarily shut down its kidney transplant program for two months, and resulted in the suspension of a nurse and demotion of a surgeon. Federal reviewers with United Network for Organ Sharing concluded human error at fault for the oversight and corrective plans that included multiple redundancies were instituted with oversight from the Pennsylvania Department of Health.
=== Aryl halide-stapled peptides === Sufficiently electrophilic aryl halides have been used as staples as they can bridge two amino acids with nucleophilic side chains, most notably two cysteines. These include fluorobenzenes and dichlorotetrazine. The diversity of aryl halides in terms of electrophilicity and regiochemistry offers a way of tuning the reactivity and tightness of the staple. The latter aspect has been applied to the tuning of secondary structure of small peptides.
Sources: en.wikipedia.org
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.
Most certificates state a percentage derived from chromatographic peak area, alongside a mass confirmation. The exact criteria and acceptance thresholds vary between laboratories.
Dry powder is kept frozen or refrigerated and protected from light and moisture. Solutions are handled cold and used promptly to limit degradation.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.